--- canonical_name: Salacia reticulata alternate_names: Kothala Himbutu, Kothalahimbutu, Kotala Himbutu, Ponkoranti, Ekanayakam canonical_topic: Salacia reticulata for Health & Longevity short_topic_lc: salacia_reticulata creation_date: 2026-0814-0422 creator_ai_fullname: Grok 4.5 --- # Salacia reticulata for Health & Longevity

Evidence Review created on 08/14/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5 **Also known as:** Kothala Himbutu, Kothalahimbutu, Kotala Himbutu, Ponkoranti, Ekanayakam ## Motivation *Salacia reticulata* is a woody climbing shrub native to Sri Lanka and southern India. Traditional Ayurvedic and Sri Lankan practice has used the root and stem for centuries as a tea or boiled extract for high blood sugar and excess body fat. Modern capsules and teas concentrate those same plant parts. The plant interests people who already treat diet, training, and sleep as the base layer and who want a meal-time tool for flatter after-meal blood-sugar curves. The core action is local in the gut: plant compounds slow the enzymes that split starch and table sugar into absorbable glucose, so a carbohydrate-rich meal produces a smaller sugar and insulin rise. Related species have been sold as food ingredients in Japan and as capsules in the United States. Human trials exist, but they are small, short, and often paid for by extract makers. Animal work also raises a pregnancy-safety concern that human trials have not tested. This review examines the human and laboratory evidence on *Salacia reticulata* for metabolic health and longevity — how the plant works, what benefits and harms the data support, and how products are typically taken and monitored. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews that discuss *Salacia reticulata* or its starch-blocking thiosugar chemistry in substantial depth. - [Salacia reticulata (Kothala himbutu) revisited; a missed opportunity to treat diabetes and obesity?](https://pubmed.ncbi.nlm.nih.gov/25889885/) - Medagama, 2015 Single-author narrative review of in-vitro, animal, and human *Salacia reticulata* work on glucose, insulin, and weight, including why fasting-glucose effects need more than a starch-enzyme block. - [Anti-diabetic and Anti-hyperlipidemic Effects and Safety of Salacia reticulata and Related Species.](https://pubmed.ncbi.nlm.nih.gov/26031882/) - Stohs & Ray, 2015 Species-spanning review of trials, lipids, antioxidants, and rodent safety. One author was affiliated with AdvoCare, a supplement firm; the paper is still the most cited safety-and-efficacy overview. - [Salacia root, a unique Ayurvedic medicine, meets multiple targets in diabetes and obesity.](https://pubmed.ncbi.nlm.nih.gov/18433791/) - Li et al., 2008 Short mechanistic review arguing Salacia root hits several diabetes and obesity targets at once — starch enzymes, fat-burning gene programs, lipase, and a blood-pressure receptor. - [A review of antidiabetic active thiosugar sulfoniums, salacinol and neokotalanol, from plants of the genus Salacia.](https://pubmed.ncbi.nlm.nih.gov/33900535/) - Morikawa et al., 2021 Chemistry-first review of salacinol and neokotalanol from the *Salacia* genus, tracing isolation, enzyme potency, and use as Japanese functional-food ingredients. - [Anti-protein glycation and free-radical scavenging properties of Sri Lankan antidiabetic medicinal plant Salacia reticulata l. (Kothala Himbutu).](https://pubmed.ncbi.nlm.nih.gov/37924066/) - Premakumara & Abeysekera, 2023 Head-to-head laboratory comparison of root, stem, leaf, twig, and fruit for anti-glycation and free-radical scavenging; root was strongest. No dedicated *Salacia reticulata* content was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io. Life Extension mentions the plant in passing inside broader articles; those mentions do not constitute a high-level overview. ## Grokipedia - [Salacia reticulata](https://grokipedia.com/page/Salacia_reticulata) Grokipedia's dedicated *Salacia reticulata* page covers taxonomy, common names, traditional use, and the main starch-blocking compounds in one place. ## Examine - [Salacia reticulata](https://examine.com/supplements/salacia-reticulata/) Examine's monograph summarizes human dosing (240–1,000 mg with carbohydrate meals), rates blood-glucose evidence, and compares potency to the prescription starch blocker acarbose. ## ConsumerLab No ConsumerLab article for *Salacia reticulata* was found. ## Systematic Reviews No systematic reviews or meta-analyses for *Salacia reticulata* were found on PubMed as of 14 August 2026. Neither a systematic review of claimed glycemic effects nor one of principal harms was identified. ## Mechanism of Action *Salacia reticulata* root and stem contain thiosugar sulfoniums — mainly salacinol, kotalanol, ponkoranol, and a 13-membered cyclic sulfoxide — that competitively inhibit intestinal α-glucosidase (the brush-border enzyme that splits maltose, sucrose, and starch fragments into glucose) and, to a lesser extent, α-amylase (the starch-cutting enzyme). This is the same pharmacologic class as acarbose. The cyclic sulfoxide was more potent than salacinol in enzyme assays ([Ozaki et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18547114/)). The block is meal-local: extracts lower glucose after sucrose or maltose, not after glucose, which needs no digestion ([Medagama, 2015](https://pubmed.ncbi.nlm.nih.gov/25889885/)). A second set of actions is used to explain fasting-glucose changes that a one-meal enzyme block does not cover. Mangiferin down-regulates hepatic fructose-1,6-bisphosphatase (FBP, a gluconeogenic enzyme) in mice ([Im et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19028559/)). In fat cells the extract activates AMPK (AMP-activated protein kinase, a cellular energy sensor), raises hormone-sensitive lipase (a fat-breakdown enzyme) and adiponectin, and suppresses fat-storage genes ([Shimada et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24838513/)). Leaf proanthocyanidins inhibit pancreatic lipase (a fat-digesting enzyme) ([Koga et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23278351/)). Related roots also inhibit aldose reductase (the glucose-to-sorbitol enzyme in nerves and lens) and engage PPAR-α (peroxisome proliferator-activated receptor-alpha, a fat-burning gene switch) ([Li et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18433791/)). The extract is a mixture. Salacinol-type inhibitors act in the gut lumen; a published human plasma half-life, tissue map, or CYP (cytochrome P450, liver drug-metabolizing enzyme) pathway for those sulfoniums was not identified. Selectivity is highest for intestinal maltase, sucrase, and isomaltase. ## Historical Context & Evolution Root and stem decoctions of *Salacia reticulata* (Kothala himbutu) have been used in Ayurvedic and Sri Lankan traditional practice for *madhumeha* (the classical diabetes picture), obesity, rheumatism, gonorrhea, and skin disease. Wooden drinking vessels carved from the plant were a folk delivery method. The original intended use was glycemic and inflammatory, not a modern longevity protocol ([Stohs & Ray, 2015](https://pubmed.ncbi.nlm.nih.gov/26031882/); one author affiliated with AdvoCare). Interest for health optimization rose after Japanese groups isolated salacinol and kotalanol as α-glucosidase inhibitors in the late 1990s and framed the extract as a food ingredient for after-meal glucose and visceral fat. Small human tea and extract trials followed in Sri Lanka, India, Japan, and Europe. Those trials showed lower HbA1c (glycated hemoglobin, a three-month blood-sugar average) and fasting glucose, not a collapse of the original claim ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/); [Shivaprasad et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23767865/)). A 2003 rat pregnancy study reported high post-implantation loss (embryos lost after attaching to the uterus) at a very large dose and remains the main reproductive-safety finding ([Ratnasooriya et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12845381/)). What changed is the commercial setting, not a reversal of the enzyme-block story. Extracts moved into Japanese foods-with-function claims and United States supplement catalogs. Reviewers then documented a different limit: composition varies by species, plant part, solvent, and harvest, and most trials are short, small, and industry-linked ([Stohs & Ray, 2015](https://pubmed.ncbi.nlm.nih.gov/26031882/); [Morikawa et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33900535/)). The current picture is a consistent small-trial glucose signal plus unresolved standardization, not a settled consensus. ## Expected Benefits ### Medium 🟩 🟩 #### Glycemic Control In people with type 2 diabetes or prediabetes, *Salacia reticulata* tea, capsules, or extract biscuits have lowered fasting glucose and HbA1c over 6–12 weeks and flattened after-meal glucose when taken with carbohydrate. The proposed mechanism is intestinal α-glucosidase block plus, with continued use, less insulin resistance. Evidence is several small randomized controlled trials (RCTs), consistent in direction, without a meta-analysis. Industry funding is common. Related-species extracts (*S. oblonga*, *S. chinensis*) show the same after-meal pattern. **Magnitude:** In a 51-person crossover tea trial, end-of-treatment HbA1c was 6.29% versus 6.65% on placebo, a 0.54-point fall versus a 0.3-point rise ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/)). In a 136-person biscuit crossover, HbA1c fell 0.35% on extract versus 0.10% on placebo (between-group about 0.25%) ([Siribaddana et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37885536/)). ### Low 🟩 #### Fasting Lipids One 6-week, 29-person RCT from Olive Lifesciences, the extract maker, reported lower low-density lipoprotein (LDL, the main circulating cholesterol particle) and fasting glucose with 500 mg/day root-bark extract; leaf extract moved fasting glucose only at week 6. No independent lipid RCT of comparable size was identified. **Magnitude:** Direction holds for 500 mg/day root-bark extract at 3 and 6 weeks in that industry trial; the indexed report does not give an LDL change figure ([Shivaprasad et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23767865/)). #### Body Weight and Fat Mass Rodent high-fat models lose visceral fat on the extract ([Kishino et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16424124/); [Shimada et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24838513/)). A 12-week extract-only RCT lowered whole-body fat mass but not fat percentage ([Park et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42187323/)). An open program added vitamin D and lifestyle to 600 mg/day ([Ofner et al., 2013](https://pubmed.ncbi.nlm.nih.gov/25008011/)). **Magnitude:** Fat mass fell 482 g versus placebo at 12 weeks (95% CI (confidence interval, the plausible range for the true effect) −907 to −58 g) in a 133-person extract-only RCT; the coprimary fat-percentage change was not significant ([Park et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42187323/)). The open combination program reported 5.3 kg (6.1%) loss versus 1.8 kg (2.1%) with lifestyle alone ([Ofner et al., 2013](https://pubmed.ncbi.nlm.nih.gov/25008011/)). #### Immune Markers and Gut Microbiota A 4-week Fujifilm RCT in 30 men aged 50–60 years used 240 mg/day extract and reported higher T-cell proliferation, a drop in a calculated "immunological age," and a large rise in fecal *Bifidobacterium*. The trial was short, male-only, and sponsor-run. **Magnitude:** T-cell proliferation index rose 0.24 versus a 0.05 fall on placebo. *Bifidobacterium* rose from 7.1% to 36.2% of the fecal profile versus 5.7% to 6.6% on placebo ([Oda et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26630568/)). ### Speculative 🟨 #### Advanced Glycation and Tissue Oxidation Root extracts inhibit protein glycation and scavenge free radicals in vitro, with root stronger than leaf or fruit. No controlled human glycation trial exists; the basis is laboratory chemistry only ([Premakumara & Abeysekera, 2023](https://pubmed.ncbi.nlm.nih.gov/37924066/)). #### Joint Inflammation Traditional use includes rheumatism. One mouse antibody-induced arthritis model found less paw swelling and bone-resorbing-cell activation without a clear drop in inflammatory messengers. Human joint trials were not identified ([Sekiguchi et al., 2010](https://pubmed.ncbi.nlm.nih.gov/19727885/)). ## Benefit-Modifying Factors - **Genetic polymorphisms:** No salacinol- or *Salacia*-specific human pharmacogenetic modifiers (transport, CYP, or disease-risk variants) have been identified. Dose is not titrated by genotype in published protocols. - **Baseline biomarkers:** People with higher fasting glucose, HbA1c, or after-meal excursions have more room to move. Near-normal values produced smaller or borderline HbA1c shifts in short arms ([Medagama, 2015](https://pubmed.ncbi.nlm.nih.gov/25889885/)). - **Sex:** No established sex difference in efficacy. The immune RCT enrolled only men ([Oda et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26630568/)). Glycemic trials enrolled mixed sexes without a published sex-stratified effect. - **Pre-existing conditions:** Prediabetes, type 2 diabetes, and mild hyperlipidemia are the populations in which benefits have been measured. The extract did not improve metabolic traits in non-obese control mice in one series ([Shimada et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24838513/)). - **Age:** Trials enrolled adults, including 50–65-year-olds. Older adults have more carbohydrate-fermentation symptoms on this drug class; they are also the group in whom flattening after-meal glucose is most often sought. ## Potential Risks & Side Effects ### Medium 🟥 🟥 #### Gastrointestinal Fermentation Symptoms Undigested starch and sucrose reach the colon and are fermented, producing gas, belching, abdominal pain, nausea, and loose stool — the class effect of α-glucosidase inhibitors. Related-species meals raised breath hydrogen in a dose-linear way. Dedicated *S. reticulata* RCTs reported no serious events and little systematic adverse-event counting. Symptoms are meal- and dose-linked and usually reversible when the product is stopped. **Magnitude:** Prevalence of bothersome gas and loose stool rises with dose and with high-starch meals; *S. oblonga* 1,000 mg raised breath hydrogen about 60% versus control, with mild flatulence ([Collene et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15975493/); [Heacock et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15635348/)). Dedicated *S. reticulata* trials did not publish an incidence figure ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/)). ### Low 🟥 #### Adverse Pregnancy Outcomes A Wistar-rat study of 10 g/kg root extract in early or mid-pregnancy raised post-implantation loss and lowered birth weight, without malformations. Human pregnancy trials do not exist. The animal dose is far above capsule intakes, but the signal is why pregnancy is treated as an absolute contraindication. **Magnitude:** Post-implantation loss rose from 4.7% to 49.3% (early) and 41.7% (mid-pregnancy); birth weight fell from 6.8 g to 5.3 g and 5.0 g ([Ratnasooriya et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12845381/)). #### Additive Glucose Lowering With Diabetes Medications The extract can lower glucose on its own. Combined with sulfonylureas (insulin-releasing drugs such as glibenclamide/glyburide), metformin, insulin, or other glucose-lowering agents, the combined effect can produce excess glucose lowering. One tea trial saw the mean glibenclamide dose fall on extract and rise on placebo. **Magnitude:** Mean daily glibenclamide fell 1.89 mg on extract and rose 2.25 mg on placebo (p = 0.07, the chance this difference is random); documented hypoglycemia events were not quantified ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/)). ### Speculative 🟨 #### High-Dose Liver-Weight Changes Some *S. oblonga* rat series reported hepatic hypertrophy (liver enlargement) at high doses. Human trials have not shown liver-enzyme injury. The basis is mixed animal histology only ([Rong et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18397819/)). #### Reduced Absorption of Other Oral Nutrients or Drugs By slowing carbohydrate digestion, the extract could change meal timing of other oral agents, as acarbose can. No human interaction-pharmacokinetic study was identified; the basis is class mechanism only. ## Risk-Modifying Factors - **Genetic polymorphisms:** No *Salacia*-specific risk alleles are known. Variants that already raise α-glucosidase-inhibitor gas (gut-microbiome pattern more than a single gene) are not used to dose this extract. - **Baseline biomarkers:** Higher fasting glucose or HbA1c increases the chance of an additive low-glucose event if other diabetes drugs are on board. Near-normal glucose lowers that risk and also lowers expected benefit. - **Sex:** Pregnancy-related fetal-loss data apply to people who can become pregnant. No other sex-specific adverse-event split has been published. - **Pre-existing conditions:** Inflammatory bowel disease and chronic diarrhea amplify fermentation symptoms. Severe liver disease and eGFR (estimated glomerular filtration rate, a kidney-filter estimate) below 30 mL/min/1.73 m² were biscuit-trial exclusions ([Siribaddana et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37885536/)). - **Age:** Older adults ferment residual carbohydrate more readily and are more often on multiple glucose-lowering drugs, raising both gut and low-glucose risk. ## Key Interactions & Contraindications - **Sulfonylureas (glibenclamide/glyburide, glipizide, glimepiride):** Caution — additive glucose lowering; monitor fingerstick glucose and watch for dose reduction of the sulfonylurea ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/)). - **Insulin and insulin-secretagogues (repaglinide, nateglinide):** Caution — same additive low-glucose risk; meal-time extract plus meal-time insulin can stack. - **Metformin and SGLT2 inhibitors (empagliflozin, dapagliflozin; drugs that dump glucose in urine):** Monitor — complementary glucose lowering; gastrointestinal overlap with metformin. - **Prescription α-glucosidase inhibitors (acarbose, miglitol):** Caution — duplicate class; more gas, cramping, and diarrhea without a proven extra HbA1c gain. - **Over-the-counter analgesics:** None — no specific *Salacia* interaction identified; gut upset, not an analgesic clash, is the usual limiter if already present. - **Berberine, white-mulberry leaf, green-coffee extract, cinnamon, chromium:** Caution — additive after-meal glucose lowering; published protocols add one change at a time and watch glucose. - **High-dose soluble fiber or orlistat-type lipase blockers:** Monitor — more bloating when starch and fat malabsorption coincide. - **Perioperative glucose control:** Caution — product labels and drug monographs describe stopping 2 weeks before planned surgery because of blood-sugar shifts. **Populations who should avoid Salacia reticulata:** - Pregnancy, including diabetes in pregnancy (rat post-implantation loss at 10 g/kg; no human pregnancy trial) ([Ratnasooriya et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12845381/)) - Breastfeeding (no lactation data) - Planned surgery within 14 days - eGFR below 30 mL/min/1.73 m² or decompensated liver disease (advanced liver failure with fluid buildup or confusion; trial exclusions; not a studied population) - Active inflammatory bowel disease with frequent diarrhea ## Risk Mitigation Strategies - **Meal-matched dosing:** Protocols take the extract only with carbohydrate-containing meals so the enzyme block meets substrate, and omit it on very-low-carbohydrate meals to cut fermentation gas. - **Low starting amount:** Protocols commonly begin at 240 mg with the largest carbohydrate meal for several days before moving toward 500–1,000 mg/day split, which limits early gas and loose stool. - **Glucose-drug audit:** When a sulfonylurea or insulin is already in use, protocols add fingerstick checks for 1–2 weeks after starting, looking for an unplanned drop. - **Pregnancy screen:** Protocols treat possible pregnancy as an absolute contraindication; the rat implantation-loss signal has no human counter-study. - **Pre-surgery hold:** Product monographs describe a 14-day hold before elective surgery so after-meal glucose is not still being flattened in recovery. - **Liver and kidney snapshot:** Protocols recheck ALT (alanine aminotransferase, a liver-injury enzyme), AST (aspartate aminotransferase, another liver-injury enzyme), and eGFR at 8–12 weeks to catch high-dose liver-weight and low-filtration signals. ## Therapeutic Protocol - **Standard extract range:** Examine and human trials describe 240–1,000 mg/day of aqueous root/stem extract, taken with carbohydrate meals; 500 mg/day was the prediabetes capsule dose ([Shivaprasad et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23767865/)). - **Traditional tea:** The Sri Lankan crossover used a standardized Kothala himbutu tea bag with meals for 3 months, not a milligram-standardized capsule ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/)). - **Japanese food-ingredient style:** Split tablets timed to meal size (example: 60 mg before breakfast and lunch, 120 mg before dinner; 240 mg/day) in the Fujifilm immune trial ([Oda et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26630568/)). - **Time of day:** With the carbohydrate-containing meals, not as a fasting or bedtime dose. The enzyme block is useful only when starch or sucrose is in the gut. - **Half-life and splitting:** Salacinol-type inhibitors act in the gut lumen; a human plasma half-life was not identified. Split doses with each carbohydrate meal rather than one daily bolus. - **Genetics:** No APOE4 (lipid-transport gene), MTHFR (folate-processing gene), COMT (catechol-clearing gene), or CYP genotype is used to choose a *Salacia* dose. - **Sex:** No sex-specific dose. People who can become pregnant are outside the studied-and-safe set. - **Age:** Adults 30–65 were typical enrollees. Older users more often start at the low end (240 mg) because fermentation symptoms rise with age. - **Baseline glucose:** Elevated fasting glucose or HbA1c is the setting in which protocols were written; near-normal values leave less to gain. - **Pre-existing disease:** Prediabetes and diet-treated or oral-agent type 2 diabetes are the studied indications. Insulin-treated and eGFR-below-30 groups were excluded from the largest trial. ## Discontinuation & Cycling - **Duration of use:** Trials lasted one meal to 3 months. The intervention is a meal-time tool, not a demonstrated lifelong necessity. - **Withdrawal:** No withdrawal syndrome (rebound hyperglycemia crisis, autonomic surge) has been described. After-meal glucose simply returns to the pre-extract pattern once the enzyme block is gone. - **Taper:** No taper is used in published protocols. The drug-class action is competitive and meal-local; stopping is abrupt. - **Cycling:** Cycling is not required to preserve efficacy. Tolerance of the α-glucosidase block has not been shown; people cycle only if gut symptoms force a break. - **Restart:** Restart with the first carbohydrate meal; no loading dose is described. ## Sourcing and Quality - **Species authentication:** Trial-grade products name *Salacia reticulata*, not a generic "Salacia." *S. oblonga* and *S. chinensis* share some thiosugars but are not interchangeable in this trial set. - **Plant part:** Root and stem (or root bark) are the parts used in the stronger glycemic trials. Leaf is weaker on α-glucosidase and stronger on lipase in vitro ([Premakumara & Abeysekera, 2023](https://pubmed.ncbi.nlm.nih.gov/37924066/)). - **Marker compounds:** Extracts used in the stronger papers state salacinol/kotalanol or mangiferin content. Stohs and Ray noted that multi-constituent activity makes a single standard hard ([Stohs & Ray, 2015](https://pubmed.ncbi.nlm.nih.gov/26031882/)). - **Third-party testing:** Identity, heavy-metal, and microbial certificates from USP (United States Pharmacopeia), NSF International, or ISO-accredited labs address wild-harvest variability and adulteration. - **Conservation:** The species is wild-harvested in Sri Lanka. Cultivated or traceable supply reduces pressure on remaining dry-forest populations. - **Brands and forms:** Japanese Salacia teas and tablet foods, Sri Lankan Kothala himbutu tea bags, and capsule extracts (including the Olive Lifesciences material used by Shivaprasad) are the forms that appear in trials. Compounding pharmacies are not the usual source. ## Practical Considerations - **Time to effect:** After-meal glucose and insulin move with the first carbohydrate meal. HbA1c and fasting glucose in trials moved over 6–12 weeks ([Jayawardena et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15707755/); [Siribaddana et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37885536/)). - **Common pitfalls:** Taking the extract away from carbohydrate; combining it with acarbose or several other starch blockers; expecting standalone fat loss; assuming "tea" and "500 mg extract" are dose-equivalent. - **Regulatory status:** In the United States the plant is sold as a dietary supplement, not a Food and Drug Administration (FDA)–approved drug. Japan has used it as a food ingredient. - **Cost and access:** Capsules and teas are inexpensive relative to prescription incretin drugs (gut-hormone medicines that raise insulin after meals) and are widely sold online. Quality, not price, is the scarce resource. - **Formulation mismatch:** Biscuits, teas, and capsules deliver different amounts of actives. Cross-trial milligram comparisons are approximate. ## Interaction with Foundational Habits - **Sleep:** Direction none to indirect. The extract is not a stimulant. Flatter after-meal glucose may reduce nocturnal glycemic swings; no sleep-architecture trial exists. Late high-starch meals plus a large dose can add gas that disturbs sleep. - **Nutrition:** Direction direct and potentiating. The enzyme block only matters when starch or sucrose is eaten. Very-low-carbohydrate patterns remove most of the rationale. High-FODMAP (fermentable oligo-, di-, and monosaccharide) or very high-starch meals increase gas. - **Exercise:** Direction none to indirect. No evidence that the extract blunts hypertrophy. After-workout carbohydrate still raises glucose, just more slowly; timing the dose with that meal is the practical point. - **Stress management:** Direction none demonstrated. Cortisol-driven glucose rises are hepatic, not starch-enzyme-dependent, so the extract does not replace sleep, training, or psychological load reduction. ## Monitoring Protocol & Defining Success Baseline work is a fasting chemistry and glycemic panel before the first dose, so later changes have an individual anchor. Ongoing checks follow the 6–12-week window in which HbA1c and safety labs moved in the tea and biscuit trials, then a longer cadence if the product continues. People already on insulin or a sulfonylurea add home glucose logs in the first 1–2 weeks. The aim is a smaller after-meal rise and, if it is elevated, a lower HbA1c, without new gut distress or unplanned lows. Typical cadence: home meal-time glucose in week 1; repeat fasting glucose, insulin, HbA1c, lipids, ALT/AST, and eGFR at 8–12 weeks, then every 3–6 months while use continues. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --- | --- | --- | --- | | Fasting glucose | 70–85 mg/dL (3.9–4.7 mmol/L) | Tracks fasting effect beyond one meal | Conventional <100 mg/dL; 8–12 h fast | | HbA1c | 4.6–5.3% | Three-month sugar exposure | Conventional <5.7%; recheck at 8–12 weeks | | Fasting insulin | 2–6 μIU/mL | Insulin demand | Conventional often <25; pair with glucose | | HOMA-IR | <1.5 | Combined glucose–insulin load | HOMA-IR (homeostatic model of insulin resistance). Conventional often <2.5–3.0; no unique *Salacia* target — track change from own baseline | | LDL cholesterol | Individual target; many functional panels use <100 mg/dL | Lipid signal in the bark-extract trial | Conventional <100–130 mg/dL depending on risk; fasting | | Triglycerides | <80–100 mg/dL | Fat handling after lipase/PPAR effects | Conventional <150 mg/dL; fasting | | ALT / AST | ALT often <25–30 U/L in functional panels | High-dose animal liver-weight signal | Conventional lab ULN (upper limit of normal) often 40–55 U/L; not fasting-dependent | | eGFR | ≥90 mL/min/1.73 m² preferred | Renal safety window used in the biscuit trial | Conventional ≥60; below 30 was an exclusion | - **After-meal glucose:** 1- and 2-hour readings after the usual carbohydrate meal, looking for a smaller peak than the personal baseline - **Gut tolerance:** gas, cramping, stool frequency in the first 2 weeks - **Energy and meal satiety:** whether the slower starch absorption is noticeable as fewer mid-afternoon drops in energy - **Unplanned lows:** shakiness or documented glucose below the personal floor if other diabetes drugs are in use ## Emerging Research - **No dedicated recruiting trial:** A 14 August 2026 ClinicalTrials.gov search for *Salacia reticulata* / kothala found no recruiting species-specific study. Completed registrations include the Anuradhapura biscuit trial ([NCT02290925](https://clinicaltrials.gov/study/NCT02290925), n = 133, published) and the Olive Lifesciences prediabetes extract study ([NCT01680211](https://clinicaltrials.gov/study/NCT01680211)). - **Combination glucose supplements:** Two completed Ohio RCTs (n = 26 each) tested a capsule of Salacia extract plus citrus bioflavonoids and chromium ([NCT05887050](https://clinicaltrials.gov/study/NCT05887050); [NCT05573607](https://clinicaltrials.gov/study/NCT05573607)). A positive result would not isolate *S. reticulata*; a null result would weaken combination-product claims. - **Incretin and insulin-signaling work:** A 2025 rodent paper reported improved insulin signaling and GLP-1 (glucagon-like peptide-1, a gut insulin-incretin hormone) ([Jung et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40523228/)). A human incretin-clamp study could strengthen a beyond-enzyme-block story; a null translation would keep fasting-glucose claims speculative. - **Fat-depot biology:** A 12-week extract-only RCT reported lower fat mass but not fat percentage ([Park et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42187323/)). Independent replication, or a null body-composition trial, would harden or shrink that signal; a 2023 mouse study reported less fat via lipid-metabolism genes ([Jung et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37685080/)). - **Reproductive safety gap:** The 2003 high-dose rat pregnancy finding has not been repeated at human-equivalent doses ([Ratnasooriya et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12845381/)). A modern segment-II study would either shrink or harden that contraindication. - **Standardization:** Morikawa's chemistry program on salacinol and neokotalanol is the path to labeled actives ([Morikawa et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33900535/)). Until trials use assayed material, conflicting potencies will remain hard to interpret. ## Conclusion *Salacia reticulata* is a traditional Sri Lankan and Indian root-and-stem preparation now sold as teas and capsules. Its strongest human finding is modest improvement in blood-sugar control in people with prediabetes or type 2 diabetes, seen in several small placebo-controlled trials of tea, extract, or extract biscuits. After-meal glucose and insulin fall when the product is taken with carbohydrate, which matches a local gut-enzyme block. Fasting sugar and three-month average sugar also moved in some of those trials, which may reflect more than a one-meal effect. Lipid and body-weight findings are thinner: one small industry trial reported lower fasting sugar and the main circulating cholesterol particle, a standalone extract trial reported a modest drop in fat mass but not fat percentage, and one open program that also used vitamin D reported larger fat loss than lifestyle alone. The risk picture in short human studies is mostly gut gas, bloating, and loose stool — the same class of effects seen with prescription starch blockers. Serious liver or kidney injury has not appeared in the available trials. A high-dose rat pregnancy study found more lost implantations and smaller pups, so pregnancy is treated as an absolute contraindication even though the human dose is far lower. Much of the clinical literature comes from companies that sell the extract. For a longevity-minded adult already managing meals and training, the plant is a meal-timed starch-absorption tool with a small, consistent sugar effect and an evidence base that remains short, small, and commercially entangled. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**